Jasper Therapeutics Inc Dossier - Source-backed chat

Jasper Therapeutics Inc

JSPRNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.28

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.60Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $19.9M

Enterprise Value $12.6M

Shares Outstanding 32.7M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Jasper Therapeutics is a clinical-stage biotechnology company focused on its lead candidate, briquilimab, a novel monoclonal antibody targeting KIT (CD117) for mast cell-driven diseases. While clinical data for briquilimab in chronic spontaneous urticaria (CSU) has been highly promising—demonstrating rapid and durable complete responses—the company is facing severe financial distress. With only $14.1 million in cash as of March 31, 2026, and a rapid cash burn rate, Jasper has initiated a comprehensive review of strategic alternatives, including a potential sale, merger, licensing deal, or orderly wind-down. Additionally, the company has received a Nasdaq non-compliance notice due to its stock price trading below $1.00. Given the binary clinical risks, imminent funding needs, and corporate restructuring uncertainties, a Hold recommendation is warranted until a clear strategic transaction or financing path is established.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.50

Mean target$9.17

High · most bullish analyst$20.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.1020%

The strategic review fails to yield a viable transaction or partnership, and the company is forced to execute an orderly wind-down of operations, resulting in minimal residual value for common stockholders.

Base CaseCentral scenario

$1.5050%

Jasper successfully secures a strategic partnership or dilutive financing package that allows it to survive as a standalone entity and initiate its Phase 2b CSU trial in late 2026, though with significant equity dilution.

Bull CaseUpside scenario

$6.0030%

A larger pharmaceutical peer acquires Jasper or licenses briquilimab under highly favorable terms, validating its best-in-class potential in CSU and providing the capital required to advance the Phase 2b study.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong clinical efficacy for briquilimab, with an 83% complete response rate at week 3 in the BEACON CSU study.
Differentiated subcutaneous dosing profile (every 8 weeks) compared to daily or more frequent competitive therapies.
Finalized Phase 2b protocol refiled with the FDA, establishing a clear regulatory pathway once funding is secured.

Key Investment Risks

Severe liquidity constraints with only $14.1 million in cash as of Q1 2026, creating an imminent need for capital.
High risk of substantial shareholder dilution or complete loss of capital if strategic alternatives fail.
Nasdaq delisting risk if the company cannot regain compliance with the $1.00 minimum bid price rule by November 30, 2026.
Intense competition in the c-Kit inhibitor space from better-capitalized peers like Celldex Therapeutics.

Thesis Invalidation Triggers

Announcement of an orderly wind-down of operations.
Failure to secure a strategic partner or funding by the end of 2026.
Delisting from the Nasdaq Capital Market.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.